{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T11:21:32Z","timestamp":1788780092224,"version":"build-2803163510"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,5,22]],"date-time":"2021-05-22T00:00:00Z","timestamp":1621641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,5,22]],"date-time":"2021-05-22T00:00:00Z","timestamp":1621641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s12325-021-01753-3","type":"journal-article","created":{"date-parts":[[2021,5,22]],"date-time":"2021-05-22T08:02:47Z","timestamp":1621670567000},"page":"3409-3426","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Safety of Patients with Hepatitis\u00a0C Virus Treated with Glecaprevir\/Pibrentasvir from Clinical Trials and Real-World Cohorts"],"prefix":"10.1007","volume":"38","author":[{"given":"Xavier","family":"Forns","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan J.","family":"Feld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas E.","family":"Dylla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislas","family":"Pol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Chayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinlin","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong","family":"Heo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Lampertico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Bondin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Tatsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Burroughs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Marcinak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenzhen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Emmett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart C.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira M.","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,22]]},"reference":[{"key":"1753_CR1","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","volume":"73","author":"European Association for the Study of the Liver","year":"2020","unstructured":"European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis\u00a0C: final update of the series. J Hepatol. 2020;73:1170\u2013218.","journal-title":"J Hepatol"},{"key":"1753_CR2","doi-asserted-by":"crossref","unstructured":"Janjua NZ, Wong S, Darvishian M, et al. The impact of SVR from direct-acting antiviral- and interferon-based treatments for HCV on hepatocellular carcinoma risk. J Viral Hepat. 2020;27:781\u2013793.","DOI":"10.1111\/jvh.13295"},{"key":"1753_CR3","doi-asserted-by":"publisher","unstructured":"Ioannou GN, Green PK, Berry K. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. J Hepatol. 2017;68:25\u201332. https:\/\/doi.org\/10.1016\/j.jhep.2017.08.030.","DOI":"10.1016\/j.jhep.2017.08.030"},{"key":"1753_CR4","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(18)32111-1","volume":"393","author":"F Carrat","year":"2019","unstructured":"Carrat F, Fontaine H, Dorival C, et al. Clinical outcomes in patients with chronic hepatitis\u00a0C after direct-acting antiviral treatment: a prospective cohort study. Lancet. 2019;393:1453\u201364.","journal-title":"Lancet"},{"key":"1753_CR5","doi-asserted-by":"publisher","first-page":"172","DOI":"10.14218\/JCTH.2018.00049","volume":"7","author":"L Kuna","year":"2019","unstructured":"Kuna L, Jakab J, Smolic R, Wu GY, Smolic M. HCV extrahepatic manifestations. J Clin Transl Hepatol. 2019;7:172\u201382.","journal-title":"J Clin Transl Hepatol"},{"key":"1753_CR6","first-page":"3","volume":"3","author":"P Cacoub","year":"2016","unstructured":"Cacoub P, Comarmond C, Domont F, Savey L, Desbois AC, Saadoun D. Extrahepatic manifestations of chronic hepatitis\u00a0C virus infection. Ther Adv Infect Dis. 2016;3:3\u201314.","journal-title":"Ther Adv Infect Dis"},{"key":"1753_CR7","unstructured":"World Health Organization. Guidelines for the screening, care and treatment of persons with chronic hepatitis\u00a0C infection; 2016. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/205035\/9789241549615_eng.pdf;jsessionid=8D2F71004784EEC3AD8BBDF63D13D49A?sequence=1. Accessed May 2020."},{"key":"1753_CR8","unstructured":"Alcorn K. France switches to simplified pangenotypic hepatitis\u00a0C treatment; 2019. https:\/\/www.worldhepatitisalliance.org\/latest-news\/infohep\/3435331\/france-switches-simplified-pangenotypic-hepatitis-c-treatment. Accessed Mar 2020."},{"key":"1753_CR9","unstructured":"Gastroenterological Society of Australia. Australian recommendations for the management of hepatitis\u00a0C virus infection: a consensus statement; 2018. https:\/\/www.hepcguidelines.org.au. Accessed Mar 2020."},{"issue":"71","key":"1753_CR10","first-page":"686","volume":"2019","author":"AASLD-IDSA Hepatitis\u00a0C Guidance Panel","year":"2019","unstructured":"AASLD-IDSA Hepatitis\u00a0C Guidance Panel. Hepatitis\u00a0C guidance 2019 update: American Association for the Study of Liver Diseases\u2013Infectious Diseases Society of America recommendations for testing, managing, and treating hepatitis\u00a0C virus infection. J Hepatol. 2019;2019(71):686\u2013721.","journal-title":"J Hepatol"},{"key":"1753_CR11","doi-asserted-by":"crossref","unstructured":"Huppe D, Serfert Y, Buggisch P, et al. [4\u00a0years of direct-acting antivirals (DAAs) in the German Hepatitis\u00a0C-Registry (DHC-R)]. Z Gastroenterol. 2019;57:27\u201336.","DOI":"10.1055\/a-0821-7188"},{"key":"1753_CR12","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1186\/s12913-019-4635-7","volume":"19","author":"A Radley","year":"2019","unstructured":"Radley A, Robinson E, Aspinall EJ, Angus K, Tan L, Dillon JF. A systematic review and meta-analysis of community and primary-care-based hepatitis\u00a0C testing and treatment services that employ direct acting antiviral drug treatments. BMC Health Serv Res. 2019;19:765.","journal-title":"BMC Health Serv Res"},{"key":"1753_CR13","doi-asserted-by":"crossref","unstructured":"Crespo J, Albillos A, Buti M, et al. Elimination of hepatitis\u00a0C. Positioning document of the Spanish Association for the Study of the Liver (AEEH). Gastroenterol Hepatol. 2019;42:579\u201392.","DOI":"10.1016\/j.gastre.2019.09.002"},{"key":"1753_CR14","doi-asserted-by":"crossref","unstructured":"de Franchis R, Baveno VI Faculty. Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015;63:743\u201352.","DOI":"10.1016\/j.jhep.2015.05.022"},{"key":"1753_CR15","doi-asserted-by":"publisher","first-page":"547","DOI":"10.5604\/01.3001.0012.0916","volume":"17","author":"JR Carvalho","year":"2018","unstructured":"Carvalho JR, Verdelho Machado M. New insights about albumin and liver disease. Ann Hepatol. 2018;17:547\u201360.","journal-title":"Ann Hepatol"},{"key":"1753_CR16","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.jhep.2018.04.013","volume":"69","author":"S Bloom","year":"2018","unstructured":"Bloom S, Kemp W, Nicoll A, et al. Liver stiffness measurement in the primary care setting detects high rates of advanced fibrosis and predicts liver-related events in hepatitis\u00a0C. J Hepatol. 2018;69:575\u201383.","journal-title":"J Hepatol"},{"key":"1753_CR17","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.jhep.2019.03.033","volume":"71","author":"A Srivastava","year":"2019","unstructured":"Srivastava A, Gailer R, Tanwar S, et al. Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease. J Hepatol. 2019;71:371\u20138.","journal-title":"J Hepatol"},{"key":"1753_CR18","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/j.clinthera.2018.05.010","volume":"40","author":"SN Kapadia","year":"2018","unstructured":"Kapadia SN, Marks KM. Hepatitis\u00a0C management simplification from test to cure: a framework for primary care providers. Clin Ther. 2018;40:1234\u201345.","journal-title":"Clin Ther"},{"key":"1753_CR19","unstructured":"AbbVie. Maviret (glecaprevir\/pibrentasvir) summary of product characteristics; 2017. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/maviret-epar-product-information_en.pdf. Accessed Mar 2020."},{"key":"1753_CR20","unstructured":"AbbVie. Mavyret (glecaprevir\/pibrentasvir) US prescribing information; 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/209394s008lbl.pdf. Accessed Mar 2020."},{"key":"1753_CR21","doi-asserted-by":"crossref","unstructured":"Zuckerman E, Gutierrez JA, Dylla DE, et al. Eight weeks treatment with glecaprevir\/pibrentasvir is safe and efficacious in an integrated analysis of treatment-naive patients with hepatitis\u00a0C virus infection. Clin Gastroenterol Hepatol. 2020;18:2544\u201353.e6.","DOI":"10.1016\/j.cgh.2020.06.044"},{"key":"1753_CR22","unstructured":"Panel A-IHCG. Recommendations for testing, managing, and treating hepatitis\u00a0C; 2020. https:\/\/www.hcvguidelines.org\/. Accessed Mar 2020."},{"key":"1753_CR23","unstructured":"MedDRA. Introductory guide MedDRA version 22.1; 2019. https:\/\/admin.new.meddra.org\/sites\/default\/files\/guidance\/file\/000354_intguide_22.1.pdf. Accessed June 2020."},{"key":"1753_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2019.12.007","volume":"18","author":"MJ Zoratti","year":"2020","unstructured":"Zoratti MJ, Siddiqua A, Morassut RE, et al. Pangenotypic direct acting antivirals for the treatment of chronic hepatitis\u00a0C virus infection: a systematic literature review and meta-analysis. EClinicalMedicine. 2020;18:","journal-title":"EClinicalMedicine"},{"key":"1753_CR25","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1186\/s12879-017-2775-0","volume":"17","author":"RW Peeling","year":"2017","unstructured":"Peeling RW, Boeras DI, Marinucci F, Easterbrook P. The future of viral hepatitis testing: innovations in testing technologies and approaches. BMC Infect Dis. 2017;17:699.","journal-title":"BMC Infect Dis"},{"key":"1753_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2016-000130","volume":"4","author":"U Sbarigia","year":"2017","unstructured":"Sbarigia U, Wirth D, Van Nuys K, et al. Economic study of the value of expanding HCV treatment capacity in Germany. BMJ Open Gastroenterol. 2017;4:","journal-title":"BMJ Open Gastroenterol"},{"key":"1753_CR27","doi-asserted-by":"publisher","first-page":"311","DOI":"10.7326\/M17-0118","volume":"167","author":"S Kattakuzhy","year":"2017","unstructured":"Kattakuzhy S, Gross C, Emmanuel B, et al. Expansion of treatment for hepatitis\u00a0C virus infection by task shifting to community-based nonspecialist providers: a nonrandomized clinical trial. Ann Intern Med. 2017;167:311\u20138.","journal-title":"Ann Intern Med"},{"key":"1753_CR28","doi-asserted-by":"publisher","first-page":"S315","DOI":"10.1016\/S0168-8278(18)30848-1","volume":"68","author":"A Wade","year":"2018","unstructured":"Wade A, Doyle J, Gane E, et al. Preliminary analysis of the Prime study; a randomized controlled trial comparing the hepatitis\u00a0C care cascade in primary vs tertiary care. J Hepatol. 2018;68:S315\u20136.","journal-title":"J Hepatol"},{"key":"1753_CR29","doi-asserted-by":"crossref","unstructured":"Syed TA, Bashir MH, Farooqui SM, et al. Treatment outcomes of hepatitis\u00a0C-infected patients in specialty clinic vs. primary care physician clinic: a comparative analysis. Gastroenterol Res Pract. 2019;2019:8434602.","DOI":"10.1155\/2019\/8434602"},{"key":"1753_CR30","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.drugpo.2017.07.021","volume":"47","author":"BL Norton","year":"2017","unstructured":"Norton BL, Fleming J, Bachhuber MA, et al. High HCV cure rates for people who use drugs treated with direct acting antiviral therapy at an urban primary care clinic. Int J Drug Policy. 2017;47:196\u2013201.","journal-title":"Int J Drug Policy"},{"key":"1753_CR31","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/cld.692","volume":"11","author":"TT Tran","year":"2018","unstructured":"Tran TT. Hepatitis\u00a0C: who should treat hepatitis\u00a0C virus? The role of the primary care provider. Clin Liver Dis (Hoboken). 2018;11:66\u20138.","journal-title":"Clin Liver Dis (Hoboken)"},{"issue":"suppl1","key":"1753_CR32","doi-asserted-by":"publisher","first-page":"S349","DOI":"10.1016\/S0168-8278(20)31197-1","volume":"73","author":"L Krassenburg","year":"2020","unstructured":"Krassenburg L, Mann R, Ramji A, et al. Identification of patients with compensated cirrhosis who can safely use protease inhibitor-based therapy for HCV infection. J Hepatol. 2020;73(suppl1):S349\u2013S350.","journal-title":"J Hepatol"},{"key":"1753_CR33","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.jhep.2019.10.020","volume":"72","author":"RS Brown Jr","year":"2020","unstructured":"Brown RS Jr, Buti M, Rodrigues L, et al. Glecaprevir\/pibrentasvir for 8\u00a0weeks in treatment-naive patients with chronic HCV genotypes 1-6 and compensated cirrhosis: the EXPEDITION-8 trial. J Hepatol. 2020;72:441\u20139.","journal-title":"J Hepatol"},{"key":"1753_CR34","doi-asserted-by":"publisher","first-page":"4033","DOI":"10.1007\/s12325-020-01449-0","volume":"37","author":"P Lampertico","year":"2020","unstructured":"Lampertico P, Mauss S, Persico M, et al. Real-world clinical practice use of 8-week glecaprevir\/pibrentasvir in treatment-naive patients with compensated cirrhosis. Adv Ther. 2020;37:4033\u201342.","journal-title":"Adv Ther"},{"key":"1753_CR35","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.cmi.2016.09.017","volume":"22","author":"I Carmona","year":"2016","unstructured":"Carmona I, Cordero P, Ampuero J, Rojas A, Romero-Gomez M. Role of assessing liver fibrosis in management of chronic hepatitis\u00a0C virus infection. Clin Microbiol Infect. 2016;22:839\u201345.","journal-title":"Clin Microbiol Infect"},{"key":"1753_CR36","doi-asserted-by":"crossref","unstructured":"Schulte B, Wubbolding M, Marra F, et al. Frequency of potential drug-drug interactions in the changing field of HCV therapy. Open Forum Infect Dis. 2020;7:ofaa040.","DOI":"10.1093\/ofid\/ofaa040"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01753-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-021-01753-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01753-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T03:53:00Z","timestamp":1623297180000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-021-01753-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,22]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["1753"],"URL":"https:\/\/doi.org\/10.1007\/s12325-021-01753-3","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,22]]},"assertion":[{"value":"9 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}